Evidence map›Paper›PMID 41683909›Full record

ArticleInternational journal of molecular sciences2026

Dynamic microRNA Signatures as Biomarkers for Cardiac Ischemia and Remodeling.

Macarena Rodríguez-Serrano, Elena Martín-García, Patricia Alonso-Andrés, Elisa Conde-Moreno, Héctor Pian, Javier Del Moral-Salmoral, Nunzio Alcharani, Miriam Menacho-Román, Lorena Crespo-Toro, Miren Edurne Ramos-Muñoz and 4 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Macarena Rodríguez-SerranoBiomarkers and Therapeutic Targets Group, Pathology Department, Ramón y Cajal Health Research Institute (IRYCIS), C/Carretera Colmenar Km 9,100, 28034 Madrid, Spain.
Elena Martín-GarcíaBiomarkers and Therapeutic Targets Group, Pathology Department, Ramón y Cajal Health Research Institute (IRYCIS), C/Carretera Colmenar Km 9,100, 28034 Madrid, Spain.ORCID 0000-0003-0223-6765
Patricia Alonso-AndrésBiomarkers and Therapeutic Targets Group, Pathology Department, Ramón y Cajal Health Research Institute (IRYCIS), C/Carretera Colmenar Km 9,100, 28034 Madrid, Spain.
Elisa Conde-MorenoBiomarkers and Therapeutic Targets Group, Pathology Department, Ramón y Cajal Health Research Institute (IRYCIS), C/Carretera Colmenar Km 9,100, 28034 Madrid, Spain.ORCID 0000-0002-3751-9602
Héctor PianBiomarkers and Therapeutic Targets Group, Pathology Department, Ramón y Cajal Health Research Institute (IRYCIS), C/Carretera Colmenar Km 9,100, 28034 Madrid, Spain.
Javier Del Moral-SalmoralBiomarkers and Therapeutic Targets Group, Pathology Department, Ramón y Cajal Health Research Institute (IRYCIS), C/Carretera Colmenar Km 9,100, 28034 Madrid, Spain.ORCID 0000-0001-9370-0257
Nunzio AlcharaniUnidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, 28223 Madrid, Spain.
Miriam Menacho-RománClinical Biochemistry Department, Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.
Lorena Crespo-ToroBiomarkers and Therapeutic Targets Group, Pathology Department, Ramón y Cajal Health Research Institute (IRYCIS), C/Carretera Colmenar Km 9,100, 28034 Madrid, Spain.
Miren Edurne Ramos-MuñozBiomarkers and Therapeutic Targets Group, Pathology Department, Ramón y Cajal Health Research Institute (IRYCIS), C/Carretera Colmenar Km 9,100, 28034 Madrid, Spain.
Carlos ZaragozaUnidad de Investigación Cardiovascular, Departamento de Cardiología, Hospital Ramón y Cajal (IRYCIS), Universidad Francisco de Vitoria, 28223 Madrid, Spain.ORCID 0000-0002-1706-8592
Luis Miguel RincónCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, 37008 Salamanca, Spain.ORCID 0000-0003-1819-5742
María G BarderasDepartment of Vascular Physiopathology, Hospital Nacional de Parapléjicos, SESCAM, 45071 Toledo, Spain.ORCID 0000-0003-4290-4721
María Laura García-BermejoBiomarkers and Therapeutic Targets Group, Pathology Department, Ramón y Cajal Health Research Institute (IRYCIS), C/Carretera Colmenar Km 9,100, 28034 Madrid, Spain.ORCID 0000-0002-8167-2276

Funding

Comunidad de Madrid CIFRA_COR-CM P2022/BMD-7223Instituto de Salud Carlos III PI18/00267Instituto de Salud Carlos III PI21/01822Instituto de Salud Carlos III PI24/01150Instituto de Salud Carlos III RD21/0005/0027
6 · The paper itself

Abstract

Myocardial infarction (MI) triggers complex pathological processes, including inflammation, hypoxia, and fibrotic remodeling. MicroRNAs (miRNAs) have emerged as promising biomarkers for cardiovascular injury; however, their expression dynamics along processes remain underexplored. We used an in vivo rat model of permanent coronary occlusion to study the molecular alterations associated with MI and its resolution in a temporal mode, including five experimental groups with five animals in each: sham, PO 24 h, PO 72 h, PO 7 d, PO 1 month. Histological analysis, serum biomarkers, and miRNA/gene expression profiles were analyzed in a time-dependent manner post-occlusion. Subsequent analysis revealed early depletion of selected circulating miRNAs (PO 24 h). Transient upregulation in cardiac tissue miRNAs, inflammatory and fibrotic gene expression (Fibronectin, Collagen, Vimentin, E-Cadherin) were observed at PO 72 h. These molecular alterations correlated with histological evidence of myocardial injury and repair. Taken together, our findings delineate the molecular timeline of MI progression and resolution and identify candidate miRNAs as sensitive and time-dependent indicators of myocardial stress, including miR-107, miR-122-5p and miR-221-3p. This integrative approach supports the use of miRNA signatures for noninvasive monitoring of cardiac injury and resolution and unveils potential therapeutic targets to reduce pathological remodeling.

Indexed as

BiomarkersMicroRNAsMyocardial InfarctionMyocardial IschemiaVentricular RemodelingAnimalsDisease Models, AnimalGene Expression ProfilingGene Expression RegulationMaleMyocardiumRatsBiomarkersMicroRNAscardiac remodelingfibrosisgene expression profilingimmune responsemicroRNA biomarkersmyocardial infarctionpermanent coronary occlusion

Identifiers

PMID41683909
PMCPMC12897856

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.